News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
529,885 Results
Type
Article (32556)
Company Profile (77)
Press Release (497246)
Multimedia
Podcasts (168)
Webinars (24)
Section
Business (180362)
Career Advice (1713)
Deals (25757)
Drug Delivery (132)
Drug Development (61131)
Employer Resources (117)
FDA (11560)
Job Trends (11254)
News (263742)
Policy (24198)
Tag
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 BioMidwest Standard (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (1)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (2)
2027 Genetown Standard (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (4)
Academia (1724)
Academic (1)
Accelerated approval (42)
ADA (34)
Adcomms (22)
Allergies (153)
Alliances (42197)
ALS (170)
Alzheimer's disease (1363)
Antibody-drug conjugate (ADC) (418)
Approvals (12046)
Artificial intelligence (635)
ASCO (259)
Autoimmune disease (275)
Automation (54)
Bankruptcy (242)
Best Places to Work (8574)
BIO (54)
BIOSECURE Act (13)
Biosimilars (206)
Biotechnology (47)
Bladder cancer (152)
Brain cancer (62)
Breast cancer (607)
Cancer (4844)
Cardiovascular disease (415)
Career advice (1489)
Career pathing (41)
CAR-T (227)
CDC (38)
Celiac Disease (1)
Cell therapy (719)
Cervical cancer (42)
Clinical research (54117)
Collaboration (1993)
Commercialization (1)
Company closure (3)
Compensation (697)
Complete response letters (65)
COVID-19 (1928)
CRISPR (94)
C-suite (1015)
Cystic fibrosis (106)
Data (6865)
Decentralized trials (3)
Denatured (56)
Depression (129)
Dermatology (73)
Diabetes (522)
Diagnostics (4617)
Digital health (48)
Diversity (9)
Diversity, equity & inclusion (34)
Drug discovery (321)
Drug pricing (187)
Drug shortages (31)
Duchenne muscular dystrophy (240)
Earnings (72117)
Editorial (66)
Employer branding (14)
Employer resources (108)
Events (83080)
Executive appointments (939)
FDA (14702)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (15)
Frontotemporal dementia (30)
Funding (1320)
Gene editing (193)
Generative AI (64)
Gene therapy (619)
GLP-1 (902)
Government (3231)
Grass and pollen (7)
Guidances (374)
Healthcare (12204)
Hematology (140)
HIV (72)
Huntington's disease (50)
Idiopathic pulmonary fibrosis (1)
IgA nephropathy (92)
Immunology and inflammation (222)
Immuno-oncology (86)
Indications (189)
Infectious disease (2173)
Inflammatory bowel disease (179)
Inflation Reduction Act (15)
Influenza (93)
Intellectual property (251)
Interviews (301)
IPO (11596)
IRA (49)
Job creations (3002)
Job search strategy (1220)
JPM (57)
Kidney cancer (18)
Labor market (82)
Layoffs (385)
Leadership (39)
Legal (6101)
Liver cancer (65)
Longevity (24)
Lung cancer (641)
Lymphoma (384)
Machine learning (45)
Management (40)
Manufacturing (1013)
Marketing (3)
MASH (199)
Medical affairs (1)
Medical device (7773)
Medtech (7881)
Mergers & acquisitions (15243)
Metabolic disorders (1354)
mRNA (172)
Multiple sclerosis (161)
NASH (18)
Neurodegenerative disease (339)
Neuropsychiatric disorders (88)
Neuroscience (2634)
Neurotech (1)
NextGen: Class of 2026 (4272)
Non-profit (2989)
Now hiring (33)
Obesity (612)
Opinion (281)
Ovarian cancer (166)
Pain (229)
Pancreatic cancer (255)
Parkinson's disease (302)
Partnered (26)
Patents (498)
Patient recruitment (503)
Peanut (35)
People (45668)
Pharmaceutical (36)
Pharmacy benefit managers (30)
Phase 1 (15862)
Phase 2 (23325)
Phase 3 (19105)
Pipeline (8357)
Policy (276)
Postmarket research (2220)
Preclinical (6817)
Press Release (44)
Prostate cancer (297)
Psychedelics (48)
Radiopharmaceuticals (293)
Rare diseases (964)
Real estate (4332)
Recruiting (50)
Regulatory (19329)
Reports (36)
Research institute (1696)
Resumes & cover letters (252)
Rett syndrome (34)
RNA editing (19)
RSV (60)
Schizophrenia (158)
Series A (240)
Series B (158)
Service/supplier (3)
Sickle cell disease (116)
Special edition (23)
Spinal muscular atrophy (133)
Sponsored (36)
Startups (2545)
State (2)
Stomach cancer (14)
Supply chain (107)
Tariffs (85)
The Weekly (110)
Vaccines (821)
Venture capital (93)
Weight loss (388)
Women's health (94)
Worklife (16)
Date
Today (4)
Last 7 days (300)
Last 30 days (1458)
Last 365 days (23504)
2026 (13008)
2025 (23434)
2024 (25748)
2023 (28727)
2022 (37453)
2021 (39576)
2020 (38302)
2019 (32407)
2018 (24510)
2017 (24365)
2016 (23788)
2015 (27574)
2014 (23027)
2013 (20068)
2012 (20617)
2011 (20550)
2010 (19252)
Location
Africa (697)
Alabama (75)
Alaska (5)
Arizona (205)
Arkansas (11)
Asia (33668)
Australia (5117)
California (10045)
Canada (3064)
China (1239)
Colorado (476)
Connecticut (477)
Delaware (318)
Europe (73813)
Florida (1707)
Georgia (329)
Hawaii (2)
Idaho (34)
Illinois (895)
India (93)
Indiana (544)
Iowa (11)
Japan (519)
Kansas (106)
Kentucky (37)
Louisiana (33)
Maine (37)
Maryland (1253)
Massachusetts (7507)
Michigan (276)
Minnesota (488)
Mississippi (3)
Missouri (92)
Montana (18)
Nebraska (17)
Nevada (103)
New Hampshire (41)
New Jersey (3109)
New Mexico (18)
New York (2805)
North Carolina (1454)
North Dakota (7)
Northern California (4972)
Ohio (286)
Oklahoma (17)
Oregon (27)
Pennsylvania (2145)
Puerto Rico (24)
Rhode Island (39)
South America (963)
South Carolina (41)
Southern California (4188)
Tennessee (193)
Texas (1631)
United States (37034)
Utah (300)
Vermont (2)
Virginia (293)
Washington D.C. (64)
Washington State (803)
West Virginia (3)
Wisconsin (100)
Wyoming (2)
529,885 Results for "gan and lee pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Gan & Lee Pharmaceuticals Signs Exclusive License Agreement with JW Pharmaceutical, the Leading South Korean Pharma, to Advance the Global Commercialization of the Innovative GLP-1 Receptor Agonist Bofanglutide
April 10, 2026
·
8 min read
Press Releases
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases -- Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.
June 12, 2026
·
7 min read
Press Releases
Gan & Lee Pharmaceuticals’ Once-Weekly Basal Insulin GZR4 Injection Meets Primary Endpoints in Two Pivotal Phase 3 Clinical Trials: SUPER-1 and SUPER-2
March 31, 2026
·
6 min read
Press Releases
Once-Monthly GLP-1 RA | Gan & Lee Pharmaceuticals Initiates Phase 3 Clinical Study (GRADUAL-3) of the First Chinese Once-Monthly GLP-1 RA for Weight Management
November 27, 2025
·
3 min read
Pharm Country
Gan & Lee Pharmaceuticals to Present Groundbreaking Data on Three Innovative Products at the American Diabetes Association’s 84th Scientific Sessions
Gan & Lee Pharmaceuticals announced the presentation of three abstracts featuring their investigational products at the American Diabetes Association’s 84th Scientific Sessions.
June 17, 2024
·
3 min read
Press Releases
Gan & Lee Pharmaceuticals Presented Multiple Results in Novel Diabetes Therapies at the American Diabetes Association’s 85th Scientific Sessions
June 23, 2025
·
9 min read
Pharm Country
Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association’s 84th Scientific Sessions
Gan & Lee Pharmaceuticals announced the results of the Phase 1b/2a clinical study of the Company’s independently developed glucagon-like peptide-1 receptor agonist, GZR18 Injection, in an obese/overweight population in China, along with the results of two other innovative insulins’ preclinical studies in poster presentations at the American Diabetes Association’s（ADA’s）84th Scientific Sessions.
June 22, 2024
·
7 min read
Press Releases
Gan & Lee Pharmaceuticals Announced First Participant Dosed in the US Phase 2 Clinical Study of Bofanglutide (GZR18) Injection for Overweight or Obesity
March 11, 2025
·
4 min read
Press Releases
ObesityWeek®️ 2024 | Gan & Lee Pharmaceuticals Orally Presents Phase 2b Clinical Data for GZR18 Injection in Chinese Overweight and Obese Adults
November 11, 2024
·
5 min read
Press Releases
Tango Therapeutics Appoints Sung Lee to Board of Directors
January 5, 2026
·
8 min read
1 of 52,989
Next
